大和降康方生物(09926-HK)目标价至58.6港元股价现跌7.34%

财华社

2021-03-03

原标题：大和降康方生物(09926-HK)目标价至58.6港元股价现跌7.34%

　　大和降康方生物(09926-HK)目标价至58.6港元及评级。康方生物近日公布，公司与中国生物制药(01177-HK)共同开发的抗PD-1单抗药物派安普利(安尼可)(研发代号：AK105)联合紫杉醇和卡铂用于局部晚期或转移性鳞状非小细胞肺癌一线治疗的III期临床试验中期分析，达到主要研究终点。

　　该公司股价现报49.25港元，跌7.34%，成交量133.90万，成交额6745.03万港元。

（文章来源：财华社）

(责任编辑：DF545)

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2116514704"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2116514704\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2116514704?lang=zh_CN&edition=fundamental","thumbnail":"https://static.tigerbbs.com/082208e3c37780dd55878056410ffa43","is_english":false,"pubTime":"2021-03-03 10:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2116514704","market":"hk","top_or_hot":-1,"title":"大和降康方生物(09926-HK)目标价至58.6港元 股价现跌7.34%","media":"财华社","content":"<html><body><div>\n<p>\r\n                原标题：大和降<a href=\"https://laohu8.com/S/90010\">康方生物</a>(09926-HK)目标价至58.6港元 股价现跌7.34%\r\n            </p>\n<p><img border=\"0\" height=\"276\" src=\"https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=116.09926&amp;imageType=k&amp;token=28dfeb41d35cc81d84b4664d7c23c49f&amp;at=1\" width=\"578\"/></p><p>　　 大和降康方生物(09926-HK)<span href=\"http://baike.eastmoney.com/item/目标\" target=\"_blank\" web=\"1\">目标</span>价至58.6<span href=\"http://baike.eastmoney.com/item/港元\" target=\"_blank\" web=\"1\">港元</span>及评级。康方生物近日公布，<span href=\"http://baike.eastmoney.com/item/公司\" target=\"_blank\" web=\"1\">公司</span>与<span><a href=\"https://laohu8.com/S/01177\">中国生物制药</a></span>(01177-HK)共同开发的抗PD-1单抗药物派安普利(安尼可)(研发代号：AK105)联合紫杉醇和卡铂用于局部晚期或转移性鳞状非小细胞肺癌一线治疗的III期临床试验中期分析，达到主要研究终点。</p><div></div>\n<p>　　该公司股价现报49.25港元，跌7.34%，<span href=\"http://baike.eastmoney.com/item/成交\" target=\"_blank\" web=\"1\">成交</span>量133.90万，成交额6745.03万港元。</p><p>（文章来源：财华社）</p>\n<p>\r\n                (责任编辑：DF545)\r\n            </p>\n</div></body></html>","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>大和降康方生物(09926-HK)目标价至58.6港元 股价现跌7.34%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n大和降康方生物(09926-HK)目标价至58.6港元 股价现跌7.34%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-03 10:39 北京时间&nbsp;&nbsp;&nbsp;<a href=http://finance.eastmoney.com/a/202103031828445419.html><strong>财华社</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>原标题：大和降康方生物(09926-HK)目标价至58.6港元 股价现跌7.34%\r\n            \n　　 大和降康方生物(09926-HK)目标价至58.6港元及评级。康方生物近日公布，公司与中国生物制药(01177-HK)共同开发的抗PD-1单抗药物派安普利(安尼可)(研发代号：AK105)联合紫杉醇和卡铂用于局部晚期或转移性鳞状非小细胞肺癌一线治疗的III期临床试验中期分析，达到...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202103031828445419.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09926","symbol_name":"康方生物","start_time":0,"source_url":"http://finance.eastmoney.com/a/202103031828445419.html","article_id":"2116514704","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/082208e3c37780dd55878056410ffa43"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2116514704","pubTimestamp":1614739140,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"大和降康方生物(09926-HK)目标价至58.6港元及评级。康方生物近日公布，公司与中国生物制药(01177-HK)共同开发的抗PD-1单抗药物派安普利(安尼可)(研发代号：AK105)联合紫杉醇和...","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":["rate"],"viewcount":null,"language":"zh","relate_stocks":{"09926":"康方生物"},"translate_title":"Daiwa Jiangkangfang Bio (09926-HK) has a target price of HK $58.6 and its share price is now down 7.34%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"90010":1,"09926":1},"content_text":"原标题：大和降康方生物(09926-HK)目标价至58.6港元 股价现跌7.34%\r\n            \n　　 大和降康方生物(09926-HK)目标价至58.6港元及评级。康方生物近日公布，公司与中国生物制药(01177-HK)共同开发的抗PD-1单抗药物派安普利(安尼可)(研发代号：AK105)联合紫杉醇和卡铂用于局部晚期或转移性鳞状非小细胞肺癌一线治疗的III期临床试验中期分析，达到主要研究终点。\n　　该公司股价现报49.25港元，跌7.34%，成交量133.90万，成交额6745.03万港元。（文章来源：财华社）\n\r\n                (责任编辑：DF545)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}